Login to Your Account



Financings Roundup

Proteon Adds $15M; Getting Closer to Novartis Option

By Jennifer Boggs


Monday, August 15, 2011
About four months after kicking off a Phase II study of lead product PRT-201 , which, if positive, could entice a buyout bid from Novartis AG under a 2009 option deal, Proteon Therapeutics Inc. is padding its coffers with a $15.2 million financing.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription